AKST1220 is a synthetic cannabinoid receptor agonist classified as a non-psychotropic cannabinoid currently under investigation for its potential to treat pain and inflammation. By selectively binding… Read more
AKST1220 is a synthetic cannabinoid receptor agonist classified as a non-psychotropic cannabinoid currently under investigation for its potential to treat pain and inflammation. By selectively binding to CB1 receptors, this compound aims to deliver therapeutic benefits without the psychoactive effects typically associated with traditional cannabinoids. This category provides essential materials for pharmaceutical research and development, including the parent drug, its acyl glucuronide metabolite, and the corresponding stable isotope labelled compound. These reference standards are vital for accurate analytical testing, supporting pharmacokinetic studies, metabolic profiling, and high-resolution mass spectrometry analysis. Laboratories utilize these high-quality compounds during method validation and quality control procedures to ensure precise identification and quantification of the drug and its metabolites throughout the analytical process.